Loading clinical trials...
Loading clinical trials...
A Phase 2 Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled, Parallel Group Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP).
Conditions
Interventions
Placebo
Avatrombopag tablets
Locations
25
United States
Pacific Cancer Medical Center, Inc
Anaheim, California, United States
Comprehensive Blood and Cancer Center
Bakersfield, California, United States
Bay Area Cancer Research Group, LLC
Concord, California, United States
Pacific Coast Hematology/Oncology Medical Group Inc.
Fountain Valley, California, United States
University of California Irvine Cancer Center
Orange, California, United States
Davis, Posteraro and Wasser, MDs, LLP
Manchester, Connecticut, United States
Start Date
February 1, 2007
Primary Completion Date
January 1, 2009
Completion Date
June 1, 2009
Last Updated
March 7, 2018
NCT06757257
NCT03010202
NCT03275454
NCT00547066
NCT04071496
NCT03443570
Lead Sponsor
Eisai Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions